Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC

Video

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Corey J. Langer, MD, Professor of Medicine, Hematology/Oncology Division, University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva) for patients with non-small cell lung cancer (NSCLC).

Langer explains that the current approval for erlotinib is in patients with unselected second- and third-line, locally advanced or metastatic NSCLC. The approval was based on clinical trials showing that the agent improved response rates, overall survival, and progression-free survival when compared to placebo. Two trials examining the agent in the frontline setting did not demonstrate a clinical benefit.

Patients with EGFR mutations derive the greatest benefit from erlotinib, even though it is not specifically approved in this patient population. For patients with EGFR mutations, Langer recommends administering erlotinib in the front-line rather than delaying until later lines of treatment.

Related Videos
Robert Huddart, PhD, leader, Clinical Academic Radiotherapy Team, The Institute of Cancer Research; professor, urological cancer, honorary consultant, Urological Oncology, The Royal Marsden NHS Foundation Trust
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD